Evidence map›Paper›PMID 30623737›Full record

ArticleStem cells and development2019

Equine Allogeneic Chondrogenic Induced Mesenchymal Stem Cells Are an Effective Treatment for Degenerative Joint Disease in Horses.

Sarah Y Broeckx, Bert Seys, Marc Suls, Aurélie Vandenberghe, Tom Mariën, Edouard Adriaensen, Jeroen Declercq, Lore Van Hecke, Gabriele Braun, Klaus Hellmann and 1 more

Open access · hybridAbstract readMulticenter StudyRandomized Controlled Trial, Veterinary
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells and development, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 5 countries.

Sarah Y Broeckx1 Global Stem cell Technology NV, Anacura Group, Evergem, Belgium.
Bert Seys2 Equine Veterinary Practice Dr Suls, SP Weert, the Netherlands.
Marc Suls2 Equine Veterinary Practice Dr Suls, SP Weert, the Netherlands.
Aurélie Vandenberghe3 Equine Veterinary Service Adriaensen-Vandenberghe, Waasmunster, Belgium.
Tom Mariën4 Equitom Equine Hospital, Meldert, Belgium.
Edouard Adriaensen3 Equine Veterinary Service Adriaensen-Vandenberghe, Waasmunster, Belgium.
Jeroen Declercq5 Veterinary Practitioner, Oudenaarde, Belgium.
Lore Van Hecke1 Global Stem cell Technology NV, Anacura Group, Evergem, Belgium.
Gabriele Braun6 Klifovet AG, Munich, Germany.
Klaus Hellmann6 Klifovet AG, Munich, Germany.
Jan H Spaas1 Global Stem cell Technology NV, Anacura Group, Evergem, Belgium.
Stem Cell Technology (Taiwan) · TWSt.Jans Gasthuis Weert · NLSwiss Institute of Equine Medicine · CHNewmarket Equine Hospital · GBON Semiconductor (Belgium) · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Degenerative joint disease is one of the main causes of equine early retirement from pleasure riding or a performance career. The disease is initially triggered by an abnormal loading of normal cartilage or a normal loading of abnormal cartilage. This primary insult is accompanied with joint inflammation, which leads to further progressive degeneration of the articular cartilage and changes in the surrounding tissues. Therefore, in search for an effective treatment, 75 adult horses with early signs of degenerative fetlock joint disease were enrolled in a randomized, multicenter, double-blinded, and placebo-controlled study. Fifty animals were injected intra-articularly with the investigational veterinary product (IVP) consisting of allogeneic chondrogenic induced mesenchymal stem cells (ciMSCs) with equine allogeneic plasma, and 25 horses were injected with 0.9% NaCl (saline) control product. From week 3 to 18 after treatment, lameness scores (P < 0.001), flexion test responses (P < 0.034), and joint effusion scores (P < 0.001) were remarkably superior in IVP-treated horses. Besides nasal discharge in both treatment groups, no adverse events were observed during the entire study period. On long-term follow-up (1 year), significantly more investigational product-treated horses were working at training level or were returned to their previous level of work (P < 0.001).

Indexed as

Horse DiseasesJoint DiseasesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAllograftsAnimalsDouble-Blind MethodFemaleFollow-Up StudiesHorsesInjections, Intra-ArticularMaleallogeneicarthrosisfield trialGCPhorseMSC

Identifiers

PMID30623737
PMCPMC6441287
OpenAlexW2908564104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.